Does Rallies show Form 4 insider transactions for AQST?

Yes. Rallies tracks AQST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AQST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.

AQST (Aquestive Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Aquestive Therapeutics, Inc. Common Stock (AQST) is a publicly traded Healthcare sector company. As of May 21, 2026, AQST trades at $4.15 with a market cap of $518.74M and a P/E ratio of -6.70. AQST moved +2.20% today. Year to date, AQST is -33.07%; over the trailing twelve months it is +74.48%. Its 52-week range spans $2.12 to $7.55. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces AQST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AQST stock inside the company?

Recent AQST insider activity includes Barber Daniel sold 8.26K, Boyd Peter E. sold 29.81K, Barber Daniel sold 180.68K, BRAENDER LORI J sold 40.10K, and Cioffi Melina sold 25.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AQST Key Metrics

Key financial metrics for AQST
Metric	Value
Price	$4.15
Market Cap	$518.74M
P/E Ratio	-6.70
EPS	$-0.62
Dividend Yield	0.00%
52-Week High	$7.55
52-Week Low	$2.12
Volume	66
Avg Volume	0
Revenue (TTM)	$50.27M
Net Income	$-68.91M
Gross Margin	63.45%

Recent AQST Insider Trades

Barber Daniel sold 8.26K (~$35.41K) on May 15, 2026.
Boyd Peter E. sold 29.81K (~$124.41K) on Mar 10, 2026.
Barber Daniel sold 180.68K (~$753.97K) on Mar 10, 2026.
BRAENDER LORI J sold 40.10K (~$167.35K) on Mar 10, 2026.
Cioffi Melina sold 25.31K (~$105.62K) on Mar 10, 2026.

Latest AQST News

Aquestive Therapeutics Q1 Revenues Up 66%, Net Loss Narrows to $8.1M — May 14, 2026
Aquestive Therapeutics narrows Q1 loss, secures $150M debt facility — May 13, 2026
Aquestive Names Thomas Zalewski Chief Legal and Compliance Officer, Grants 100K RSUs and 75K Options — Mar 20, 2026
Cantor Cuts Aquestive Price Target 47% to $8, Triggering 37% Share Plunge — Mar 12, 2026
Aquestive Therapeutics Posts 10% Q4 Revenue Gain, Secures RTW Funding for Anaphylm — Mar 5, 2026

AQST Analyst Consensus

8 analysts cover AQST: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.

Common questions about AQST

Who is trading AQST stock inside the company?: Recent AQST insider activity includes Barber Daniel sold 8.26K, Boyd Peter E. sold 29.81K, Barber Daniel sold 180.68K, BRAENDER LORI J sold 40.10K, and Cioffi Melina sold 25.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AQST?: Yes. Rallies tracks AQST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AQST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.